These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 38196545)

  • 81. The liver cancer immune microenvironment: Therapeutic implications for hepatocellular carcinoma.
    Donne R; Lujambio A
    Hepatology; 2023 May; 77(5):1773-1796. PubMed ID: 35989535
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Efficacy of immunotherapy in hepatocellular carcinoma: Does liver disease etiology have a role?
    Pinto E; Meneghel P; Farinati F; Russo FP; Pelizzaro F; Gambato M
    Dig Liver Dis; 2024 Apr; 56(4):579-588. PubMed ID: 37758610
    [TBL] [Abstract][Full Text] [Related]  

  • 83. [Status Quo and Development of Immunotherapy for Hepatocellular Carcinoma].
    Wang T; Wang WT
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2023 May; 54(3):692-698. PubMed ID: 37248607
    [TBL] [Abstract][Full Text] [Related]  

  • 84. The dual checkpoint blockade in unresectable hepatocellular carcinoma: opportunities emerging in clinical trials.
    Cammarota A; Zanuso V; D'Alessio A; Pressiani T; Bozzarelli S; Personeni N; Rimassa L
    Expert Opin Investig Drugs; 2022 Apr; 31(4):425-435. PubMed ID: 35152830
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Fibrolamellar hepatocellular carcinoma treated with atezolizumab and bevacizumab: two case reports.
    Al Zahrani A; Alfakeeh A
    J Med Case Rep; 2021 Mar; 15(1):132. PubMed ID: 33722275
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Treatment-related adverse events of first-line immunotherapy versus sorafenib for advanced hepatocellular carcinoma: a meta-analysis.
    Rizzo A; Carloni R; Ricci AD; Cusmai A; Laforgia M; Calabrò C; Ungaro V; Oreste D; Sollitto M; Palmiotti G; Brandi G
    Expert Opin Drug Saf; 2023 Apr; 22(4):323-329. PubMed ID: 36426773
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Atezolizumab plus Bevacizumab versus Sorafenib for Unresectable Hepatocellular Carcinoma: Results from Older Adults Enrolled in the IMbrave150 Randomized Clinical Trial.
    Li D; Toh HC; Merle P; Tsuchiya K; Hernandez S; Verret W; Nicholas A; Kudo M
    Liver Cancer; 2022 Dec; 11(6):558-571. PubMed ID: 36589722
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Immunotherapeutic Approaches for Treating Hepatocellular Carcinoma.
    Shen W; Chen Y; Lei P; Sheldon M; Sun Y; Yao F; Ma L
    Cancers (Basel); 2022 Oct; 14(20):. PubMed ID: 36291797
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Combination of alpha-fetoprotein and neutrophil-to-lymphocyte ratio to predict treatment response and survival outcomes of patients with unresectable hepatocellular carcinoma treated with immune checkpoint inhibitors.
    Zhu HF; Feng JK; Xiang YJ; Wang K; Zhou LP; Liu ZH; Cheng YQ; Shi J; Guo WX; Cheng SQ
    BMC Cancer; 2023 Jun; 23(1):547. PubMed ID: 37322411
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Atezolizumab Plus Bevacizumab in Patients with Advanced and Progressing Hepatocellular Carcinoma: Retrospective Multicenter Experience.
    Sinner F; Pinter M; Scheiner B; Ettrich TJ; Sturm N; Gonzalez-Carmona MA; Waidmann O; Finkelmeier F; Himmelsbach V; De Toni EN; Ben Khaled N; Mohr R; Fründt TW; Kütting F; Bömmel FV; Lieb S; Krug S; Bettinger D; Schultheiß M; Jochheim LS; Best J; Müller C; Keitel V; Venerito M
    Cancers (Basel); 2022 Dec; 14(23):. PubMed ID: 36497447
    [TBL] [Abstract][Full Text] [Related]  

  • 91. The role of lenvatinib in the era of immunotherapy of hepatocellular carcinoma.
    Lee MMP; Chan LL; Chan SL
    J Liver Cancer; 2023 Sep; 23(2):262-271. PubMed ID: 37589044
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Outcomes and Toxicities of Modern Combined Modality Therapy with Atezolizumab Plus Bevacizumab and Radiation Therapy for Hepatocellular Carcinoma.
    Manzar GS; De BS; Abana CO; Lee SS; Javle M; Kaseb AO; Vauthey JN; Tran Cao HS; Koong AC; Smith GL; Taniguchi CM; Holliday EB; Das P; Koay EJ; Ludmir EB
    Cancers (Basel); 2022 Apr; 14(8):. PubMed ID: 35454808
    [TBL] [Abstract][Full Text] [Related]  

  • 93. The Evolving Scenario in the Assessment of Radiological Response for Hepatocellular Carcinoma in the Era of Immunotherapy: Strengths and Weaknesses of Surrogate Endpoints.
    Giuffrida P; Celsa C; Antonucci M; Peri M; Grassini MV; Rancatore G; Giacchetto CM; Cannella R; Incorvaia L; Corsini LR; Morana P; La Mantia C; Badalamenti G; Brancatelli G; Cammà C; Cabibbo G
    Biomedicines; 2022 Nov; 10(11):. PubMed ID: 36359347
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Immune checkpoint inhibitors in HCC: Cellular, molecular and systemic data.
    Harkus U; Wankell M; Palamuthusingam P; McFarlane C; Hebbard L
    Semin Cancer Biol; 2022 Nov; 86(Pt 3):799-815. PubMed ID: 35065242
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Combination checkpoint blockade for metastatic cutaneous malignancies in kidney transplant recipients.
    Trager MH; Coley SM; Dube G; Khan S; Ingham M; Samie FH; Geskin LJ; McDonnell D; Brouder D; Saenger Y; Carvajal R
    J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32503950
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Cost-effectiveness of Atezolizumab Plus Bevacizumab vs Sorafenib as First-Line Treatment of Unresectable Hepatocellular Carcinoma.
    Su D; Wu B; Shi L
    JAMA Netw Open; 2021 Feb; 4(2):e210037. PubMed ID: 33625508
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Immunotherapies for hepatocellular carcinoma.
    Llovet JM; Castet F; Heikenwalder M; Maini MK; Mazzaferro V; Pinato DJ; Pikarsky E; Zhu AX; Finn RS
    Nat Rev Clin Oncol; 2022 Mar; 19(3):151-172. PubMed ID: 34764464
    [TBL] [Abstract][Full Text] [Related]  

  • 98. The Role of Immune Checkpoint Blockade in the Hepatocellular Carcinoma: A Review of Clinical Trials.
    Ozer M; George A; Goksu SY; George TJ; Sahin I
    Front Oncol; 2021; 11():801379. PubMed ID: 34956912
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Renal allograft rejection after treatment with nivolumab in patients with metastatic renal cell carcinoma.
    Ishikawa G; Sugiyama T; Ito T; Otsuka A; Miyake H
    Int Cancer Conf J; 2021 Apr; 10(2):116-118. PubMed ID: 33786286
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Use of Antibiotics during Immune Checkpoint Inhibitor Treatment Is Associated with Lower Survival in Hepatocellular Carcinoma.
    Cheung KS; Lam LK; Seto WK; Leung WK
    Liver Cancer; 2021 Nov; 10(6):606-614. PubMed ID: 34950183
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.